Zhou Peng-Yang, Zhu De-Xiang, Chen Yi-Jiao, Feng Qing-Yang, Mao Yi-Hao, Zhuang Ao-Bo, Xu Jian-Min
Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, China.
World J Gastrointest Oncol. 2024 Mar 15;16(3):787-797. doi: 10.4251/wjgo.v16.i3.787.
Patatin like phospholipase domain containing 8 (PNPLA8) has been shown to play a significant role in various cancer entities. Previous studies have focused on its roles as an antioxidant and in lipid peroxidation. However, the role of PNPLA8 in colorectal cancer (CRC) progression is unclear.
To explore the prognostic effects of PNPLA8 expression in CRC.
A retrospective cohort containing 751 consecutive CRC patients was enrolled. PNPLA8 expression in tumor samples was evaluated by immunohistochemistry staining and semi-quantitated with immunoreactive scores. CRC patients were divided into high and low PNPLA8 expression groups based on the cut-off values, which were calculated by X-tile software. The prognostic value of PNPLA8 was identified using univariate and multivariate Cox regression analysis. The overall survival (OS) rates of CRC patients in the study cohort were compared with Kaplan-Meier analysis and Log-rank test.
PNPLA8 expression was significantly associated with distant metastases in our cohort ( = 0.048). CRC patients with high PNPLA8 expression indicated poor OS (median OS = 35.3, = 0.005). CRC patients with a higher PNPLA8 expression at either stage I and II or stage III and IV had statistically significant shorter OS. For patients with left-sided colon and rectal cancer, the survival curves of two PNPLA8-expression groups showed statistically significant differences. Multivariate analysis also confirmed that high PNPLA8 expression was an independent prognostic factor for overall survival (hazard ratio HR = 1.328, 95%CI: 1.016-1.734, = 0.038).
PNPLA8 is a novel independent prognostic factor for CRC. These findings suggest that PNPLA8 is a potential target in clinical CRC management.
含帕他汀样磷脂酶结构域8（PNPLA8）已被证明在多种癌症实体中发挥重要作用。先前的研究集中在其作为抗氧化剂以及在脂质过氧化中的作用。然而，PNPLA8在结直肠癌（CRC）进展中的作用尚不清楚。
探讨PNPLA8表达在CRC中的预后影响。
纳入一个包含751例连续CRC患者的回顾性队列。通过免疫组织化学染色评估肿瘤样本中PNPLA8的表达，并通过免疫反应评分进行半定量。根据X-tile软件计算的临界值，将CRC患者分为PNPLA8高表达组和低表达组。使用单因素和多因素Cox回归分析确定PNPLA8的预后价值。采用Kaplan-Meier分析和对数秩检验比较研究队列中CRC患者的总生存率（OS）。
在我们的队列中，PNPLA8表达与远处转移显著相关（P = 0.048）。PNPLA8高表达的CRC患者显示出较差的OS（中位OS = 35.3，P = 0.005）。在I期和II期或III期和IV期PNPLA8表达较高的CRC患者，其OS在统计学上显著缩短。对于左侧结肠癌和直肠癌患者，两个PNPLA8表达组的生存曲线显示出统计学上的显著差异。多因素分析还证实，PNPLA8高表达是总生存的独立预后因素（风险比HR = 1.328，95%CI：1.016 - 1.734，P = 0.038）。
PNPLA8是CRC的一个新的独立预后因素。这些发现表明PNPLA8是临床CRC管理中的一个潜在靶点。
